Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The new thrombolytic agents].

J P Bassand1

  • 1Service de Soins intensife cardiologiques et d'Expiorations foncitonnelles cardiovasculaires, CHU Saint-Jacques, Besancon.

Annales De Cardiologie Et D'Angeiologie
|September 30, 1989
PubMed
Summary

New thrombolytic agents, including tissue plasminogen activator and anistreplase (APSAC), offer similar reperfusion rates for myocardial infarction. APSAC shows a lower reobstruction rate than tissue plasminogen activator, with both reducing mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[When to suspect pulmonary embolism in a patient with deep venous thrombosis?].

Annales de cardiologie et d'angeiologie·2002
Same author

The Cardiology Information System: the need for data standards for integration of systems for patient care, registries and guidelines for clinical practice.

European heart journal·2002
Same author

[The status of clinical research in France].

Archives des maladies du coeur et des vaisseaux·2002
Same author

Intracoronary stent implantation under intracoronary ultrasound guidance with aspirin and ticlopidine therapy.

Chinese medical journal·2002
Same author

Use of dobutamine stress echocardiography in detecting silent myocardial ischaemia in asymptomatic diabetic patients: a comparison with thallium scintigraphy and exercise testing.

Diabetic medicine : a journal of the British Diabetic Association·2001
Same author

Partnership in cardiovascular medicine. A key to success not only for professional organizations.

European heart journal·2001

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombolytic Therapy

Context:

  • Emerging thrombolytic agents like tissue plasminogen activator (tPA) and anistreplase (APSAC) are becoming available.
  • Intravenous administration of these agents achieves reperfusion rates comparable to intracoronary streptokinase.

Purpose:

  • To compare the efficacy and safety of tPA and APSAC in treating acute myocardial infarction.
  • To evaluate repermeabilization rates, secondary reobstruction, infarct size, left ventricular function, and mortality.

Summary:

  • Both tPA and APSAC demonstrate comparable repermeabilization rates (approx. 70%).
  • APSAC exhibits a lower secondary reobstruction rate (10%) compared to tPA (17%), potentially due to its longer half-life.
  • Both agents effectively limit infarct size, preserve left ventricular function, and reduce both immediate and long-term mortality.

Impact:

  • These findings support the use of tPA and APSAC in acute myocardial infarction management.
  • Understanding reobstruction rates and half-lives can guide therapeutic choices.
  • Both agents offer significant benefits in reducing mortality and improving cardiac function post-infarction.

Related Experiment Videos